Dihydroergotamine mesilate nasal spray

Abstract

The invention provides a dihydroergotamine mesilate nasal spray. A used spraying device comprises a spray bottle and a spray head, and is characterized in that the spray bottle comprises a casing (1) and a liner (2) with 1.5 ml volume; the liner of the spray bottle is in a shape of a cylinder, the combination of a cylinder and a conoidcone, or the combination of a cylinder, a conoidcone and a cylinder with a smaller diameter; the casing of the spray bottle is provided with the same shape, size and interface part with a spray bottle of a 10 ml spraying agent device sold in the market presently; and the spray head adopts a spray head of the 10 ml spraying agent device sold in the market presently. The dihydroergotamine mesilate nasal spray provided by the invention has the advantages of few residues, high safety and multiple times of effective spraying, the production cost can be reduced, and the medicine waste is prevented.

Description

Technical field: [0001] The invention relates to a dihydroergotamine mesylate nasal spray, in particular to a dihydroergotamine mesylate nasal spray using a spray bottle with a volume of 1.5ml. Background technique: [0002] Dihydroergotamine mesylate is a semi-synthetic ergotamine, which mainly contracts the dilated extracranial arteries through direct contraction of smooth muscle, and may also activate 5-HT receptors on the arterial wall to make cerebral arteries The excessive expansion and pulsation of blood vessels return to normal, thereby reducing headaches. Clinically, it is mainly used for the treatment of migraine. [0003] Dihydroergotamine mesylate was first marketed abroad (1946) in the form of injection, the original manufacturer: Valeant (USA), trade name: D.H.E.45, specification: 1ml: 1mg. Advantages of the injection: rapid onset of action, 70-80% of patients' symptoms were significantly relieved 2 hours after administration. Shortcoming: 1, administration ...

AI Technical Summary

Problems solved by technology

Disadvantages: 1. Inconvenient administration: patients can only go to the hospital for treatment when they have headaches, and it is impossible to inject them by themselves

2. Migraine is a chronic disease, and the route of injection is not suitable for long-term administration

3. There are many adverse reactions, mainly severe and fatal cardiac adverse reactions (coronary artery spasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, ventricular fibrillation, cardiac valve fibrosis, etc.)

[0005] The dihydroergotamine mesylate nasal spray produced by Valeant is filled with liquid medicine in a spray bottle with a volume of about 3.5ml, which is compatible with the conventional spray head, conventional spray bottle and conventional spray bottle of the existing widely used common spray device. The production line of the filling equipment is incompatible, and the introduction of a new production line is more expensive. At the same time, because the volume of the spray bottle is relatively large compared to the small volume of liquid medicine (1ml), the liquid medicine only exists at the bottom of the spray bottle, and the liquid level Low, the depth of the immersion pipette is insufficient, resulting in incomplete absorption of the liquid medicine, resulting in less effective spraying times, more residues, and large waste. Although the defect of insufficient effective spraying times can be solved by increasing the filling volume of the liquid medicine , but further increased the waste of expensive liquid medicine, leading to high drug prices and increasing the financial burden on patients

Images